Health

U.S. officials authorize 4th dose of Pfizer COVID-19 shot for Americans 50 and up

U.S. regulators have authorized a fourth dose of Pfizer-BioNTech's COVID-19 vaccine for Americans 50 and older because of concerns about waning immunity in the age group, the drugmakers said on Tuesday.

Additional booster also authorized for people aged 12 and older with compromised immune systems

A patient gets a dose of Comirnaty, the Pfizer-BioNTech vaccine against COVID-19. (Lukas Barth/Reuters)

U.S. regulators have authorized a fourth dose of Pfizer-BioNTech's COVID-19 vaccine for Americans 50 and older.

The U.S. Food and Drug Administration also authorized an additional booster of the vaccine for people aged 12 and older with compromised immune systems, the regulatory body announced on Tuesday, with the U.S. Centers for Disease Control and Prevention (CDC) backing both uses.

"These updated recommendations acknowledge the increased risk of severe disease in certain populations including those who are elderly or over the age of 50 with multiple underlying conditions, along with the currently available data on vaccine and booster effectiveness," the CDC said in a statement.

During the recent Omicron surge, those who were boosted were 21 times less likely to die from COVID-19 compared to those who were unvaccinated, and seven times less likely to be hospitalized, CDC data shows.

The CDC's updated recommendations will mean those at-risk individuals who had a third dose at least four months ago will be eligible for yet another mRNA booster "to increase their protection against severe disease from COVID-19."

Separately and in addition, based on newly published data, adults who received a primary vaccine and booster dose of Johnson & Johnson's Janssen COVID-19 vaccine at least four months ago may now receive a second booster dose using an mRNA COVID-19 vaccine.

The authorization comes as some scientists have raised concerns about the highly contagious BA.2 Omicron subvariant, which has driven new spikes in COVID-19 cases in other countries.

COVID-19 cases in the United States have dropped sharply since a record surge in January, but have seen a small uptick over the past week, according to CDC data.

"While this EUA [emergency use authorization] will help address a current need for some, we're working diligently to develop an updated vaccine that not only protects against current COVID-19 strains, but also provides more durable responses," Pfizer chief executive Albert Bourla said in a statement.

Pfizer and BioNTech originally asked for the next booster doses to be authorized for people 65 and older in a submission citing data collected in Israel, where a second booster is already authorized for many people over age 18. The companies did not explain why the age range had been expanded.

Scientists and officials have debated whether young, healthy people will need a fourth shot. A study of Israeli health-care workers suggested that the fourth dose added little additional protection in the age group.

Biden administration officials have said that the U.S. government currently has enough doses of the vaccines to meet the demand for another round of booster shots in older Americans, even as funding for the U.S. pandemic response has all but run out.

They say that unless Congress approves more spending, the government will likely not be able to pay for future inoculations, if they are needed, particularly if the vaccines need to be redesigned to target new variants.

Here in Canada, fourth doses are already being offered to people in certain high-risk groups, such as residents of long-term care or those who are immunocompromised.

Add some “good” to your morning and evening.

A variety of newsletters you'll love, delivered straight to you.

Sign up now

Comments

To encourage thoughtful and respectful conversations, first and last names will appear with each submission to CBC/Radio-Canada's online communities (except in children and youth-oriented communities). Pseudonyms will no longer be permitted.

By submitting a comment, you accept that CBC has the right to reproduce and publish that comment in whole or in part, in any manner CBC chooses. Please note that CBC does not endorse the opinions expressed in comments. Comments on this story are moderated according to our Submission Guidelines. Comments are welcome while open. We reserve the right to close comments at any time.

Become a CBC Member

Join the conversation  Create account

Already have an account?

now